(Q36952042)

17 August 2017

1 reference

title

Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective (English)

1 reference

17 August 2017

Konstantin V Balakin

1

1 reference

17 August 2017

Yan A Ivanenkov

series ordinal

2

1 reference

17 August 2017

Alex S Kiselyov

series ordinal

3

1 reference

17 August 2017

Sergey E Tkachenko

series ordinal

4

1 reference

17 August 2017

publication date

1 September 2007

1 reference

Anti-Cancer Agents in Medicinal Chemistry

17 August 2017

published in

1 reference

17 August 2017

volume

7

1 reference

17 August 2017

issue

5

1 reference

17 August 2017

page(s)

576-592

1 reference

Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer

17 August 2017

cites work

1 reference

30 December 2023

https://opencitations.net/index/api/v1/citations/10.1158/1078-0432.CCR-06-0429

CBHA is a family of hybrid polar compounds that inhibit histone deacetylase, and induces growth inhibition, cell cycle arrest and apoptosis in human endometrial and ovarian cancer cells

1 reference

30 December 2023

https://opencitations.net/index/api/v1/citations/10.1159/000092585

Isolation and structural elucidation of new cyclotetrapeptides, trapoxins A and B, having detransformation activities as antitumor agents.

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.43.1524

Identifiers

DOI

10.2174/187152007781668698

1 reference

17 August 2017

1 reference